Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.62 |
| ▸ | EBP | Q15125 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1469874 | 1.00 | SIGMAR1 (0.62) | SIGMAR1EBPKDM4EALDH1A1POLB | |
| SCHEMBL4021413 | 0.94 | SIGMAR1 (0.66) | SIGMAR1EBPKDM4EALDH1A1POLB | |
| SCHEMBL11131491 | 0.92 | SIGMAR1 (0.69) | SIGMAR1EBPKDM4EALDH1A1POLB | |
| SCHEMBL9449900 | 0.92 | SIGMAR1 (0.69) | SIGMAR1EBPKDM4EALDH1A1POLB | |
| SCHEMBL1564250 | 0.86 | SIGMAR1 (0.55) | SIGMAR1EBPKDM4EALDH1A1POLB | |
| SCHEMBL296049 | 0.86 | SIGMAR1 (0.55) | SIGMAR1EBPKDM4EALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL11412105 | 0.82 | SIGMAR1 (0.67) | SIGMAR1EBPKDM4EALDH1A1POLB | |
| SCHEMBL10138821 | 0.80 | SIGMAR1 (0.84) | SIGMAR1EBPKDM4EALDH1A1POLB | |
| SCHEMBL8283672 | 0.80 | SIGMAR1 (0.84) | SIGMAR1EBPKDM4EALDH1A1POLB | |
| SCHEMBL8283678 | 0.80 | SIGMAR1 (0.84) | SIGMAR1EBPKDM4EALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | claimed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | claimed |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2005-11-10 | — | — | US | claimed |
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | claimed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | claimed |
| JP-58125767-A | — | — | None | — | — | JP | disclosed |
| US-RE42353-E1 | Quinazoline derivatives and pharmaceutical compositions containing them | ASTRAZENECA UK LIMITED (GB) | 2011-05-10 | — | — | US | disclosed |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 2011-03-24 | — | — | US | disclosed |
| EP-1528925-B1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-7504416-B2 | 4-substituted quinolines as antitumor agents | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | WAKAMOTO PHARMACEUTICAL CO., LTD (JP) | 2008-03-27 | — | — | US | disclosed |
| WO-1998013354-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ZENECA LIMITED (GB) | 1998-04-02 | — | — | WO | disclosed |
| EP-0557818-B1 | Process for the preparation of N-(2-hydroxypropyl)-2,6-dimethylmorpholin | BASF AG (DE) | 1996-08-28 | — | — | EP | disclosed |
| US-5391734-A | Preparation of N-(2-hydroxypropyl)-2,6-dimethylmorpholine | BASF AKTIENGESELLSCHAFT (DE) | 1995-02-21 | — | — | US | disclosed |
| EP-0557818-A2 | Process for the preparation of N-(2-hydroxypropyl)-2,6-dimethylmorpholin | BASF Aktiengesellschaft (DE) | 1993-09-01 | — | — | EP | disclosed |
| US-5240925-A | FUNGICIDAL 2-ARYL-2-CYANO-2-(HETEROCYCLYLALKYL)ETHYL-1,2,4-TRIAZOLES | ROHM AND HAAS COMPANY (US) | 1993-08-31 | — | — | US | disclosed |
| EP-0529973-A1 | Fungicidal 2-aryl-2-cyano-2-(heterocyclylalkyl)ethyl-1,2,4-triazoles | ROHM AND HAAS COMPANY (US) | 1993-03-03 | — | — | EP | disclosed |
| US-4455168-A | CONTAINING A HETEROCYCLIC, HYDROXY AMINE OR AMIDE | RICOH COMPANY, LTD. (JP) | 1984-06-19 | — | — | US | disclosed |
| JP-S58125767-A | INK FOR JET RECORDING | RICOH CO LTD | 1983-07-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076760-A1 | 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION | GABRA5, GABRA1, GABRB1 | SIGMAR1 759/4885EBP 203/4885KDM4E 2138/4885 |
| US-20110071144-A1 | QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NR5A1, NR5A2, CNKSR1 | SIGMAR1 24/4885EBP 2711/4885KDM4E 3515/4885 |
| US-20050250797-A1 | Quinzoline derivatives for use in the treatment of cancer | TPD52L2, NQO2, CCNI | SIGMAR1 360/4885EBP 3668/4885KDM4E 1320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.